1 / 11

July 12, 2014

NRG Oncology General Session. Welcome Philip J. DiSaia , MD NRG Oncology Accrual Activity Walter J. Curran, MD Protocols in Development Mitch Machtay , MD Protocol Activations   J. Tate Thigpen, MD Membership & Grant Activity Larry Wickerham, MD. July 12, 2014.

solana
Download Presentation

July 12, 2014

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. NRG Oncology General Session Welcome Philip J. DiSaia, MD NRG Oncology Accrual Activity Walter J. Curran, MD Protocols in Development Mitch Machtay, MD Protocol Activations   J. Tate Thigpen, MD Membership & Grant Activity Larry Wickerham, MD July 12, 2014

  2. NRG Oncology Participation ActivityMarch 1 – June 30, 2014Walter J. Curran, Jr., M.D.Group Chair July 12, 2014

  3. NRG Oncology AccrualPurpose of this Discussion • Monitor Enrollment Trends & Opportunities • Identify Issues with Long Standing Members • Create Healthy Rivalries/Competition • Identity of NRG Oncology Membership

  4. NRG Accrual by Disease Site*(March – June 2014) *Includes DCP Trials

  5. NRG Accrual by Membership Category*(March – June 2014) *Includes Non-Companion DCP Trials

  6. NRG Top 10 Accruing LAPS Networks(March – June 2014)

  7. NRG Top 10 CCOP Networks(March – June 2014)

  8. NRG Top 10 Non- LAPS/CCOP Members (March – June 2014)

  9. Top 10 Accruing NRG Protocols(March – June 2014)

  10. NRG Oncology Main Member, LAPS, & CCOP Institutions June 2014

  11. Robust Enrollment for First Quarter • Enrollment Mainly to “Legacy” Phase III Trials • DCP Trial Enrollment Will Presented Separately • Will Monitor Enrollment to New NRG Trials • Need for New Trials across All Disease Sites • Such Reports will be on Website/Newsletters NRG Oncology Accrual: Summary

More Related